IL235991A - Phenyl triazole sequestration and its use in modulating the gabaa receptor complex - Google Patents

Phenyl triazole sequestration and its use in modulating the gabaa receptor complex

Info

Publication number
IL235991A
IL235991A IL235991A IL23599114A IL235991A IL 235991 A IL235991 A IL 235991A IL 235991 A IL235991 A IL 235991A IL 23599114 A IL23599114 A IL 23599114A IL 235991 A IL235991 A IL 235991A
Authority
IL
Israel
Prior art keywords
modulating
receptor complex
triazole derivative
gabaa receptor
phenyl triazole
Prior art date
Application number
IL235991A
Other languages
English (en)
Hebrew (he)
Other versions
IL235991A0 (en
Original Assignee
Saniona Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona Aps filed Critical Saniona Aps
Publication of IL235991A0 publication Critical patent/IL235991A0/en
Publication of IL235991A publication Critical patent/IL235991A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL235991A 2012-06-26 2014-11-30 Phenyl triazole sequestration and its use in modulating the gabaa receptor complex IL235991A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664288P 2012-06-26 2012-06-26
DKPA201270369 2012-06-26
PCT/EP2013/063194 WO2014001282A1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Publications (2)

Publication Number Publication Date
IL235991A0 IL235991A0 (en) 2015-02-01
IL235991A true IL235991A (en) 2017-07-31

Family

ID=49782300

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235991A IL235991A (en) 2012-06-26 2014-11-30 Phenyl triazole sequestration and its use in modulating the gabaa receptor complex

Country Status (13)

Country Link
US (2) US9475797B2 (enExample)
EP (1) EP2885290B1 (enExample)
JP (1) JP6223443B2 (enExample)
KR (1) KR20150033679A (enExample)
CN (1) CN104411703A (enExample)
AU (1) AU2013283488A1 (enExample)
BR (1) BR112014032501A2 (enExample)
CA (1) CA2876780A1 (enExample)
IL (1) IL235991A (enExample)
IN (1) IN2014DN11027A (enExample)
MX (1) MX2014014872A (enExample)
RU (1) RU2014149123A (enExample)
WO (1) WO2014001282A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
IL296716A (en) 2020-03-26 2022-11-01 Richter Gedeon Nyrt History of naphthyridine and pyrido[4,3-c]pyridazine as gabaa alpha 5 receptor modulators
CN115461337A (zh) * 2020-05-13 2022-12-09 豪夫迈·罗氏有限公司 作为GABA A α5 PAM的新型三唑基衍生物
EP3992188A1 (en) * 2020-10-29 2022-05-04 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116462664B (zh) * 2022-03-08 2025-07-01 上海赛默罗生物科技有限公司 吡唑环类化合物、其制备方法、组合物及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7296896A (en) 1995-11-01 1997-05-22 Novartis Ag Purine derivatives and processes for their preparation
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
JP2003531111A (ja) 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
IL150060A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel purines
WO2001044259A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Purine derivatives
DE60205376T2 (de) 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US7176312B2 (en) 2001-10-12 2007-02-13 The Scripps Research Institute Kinase inhibitor scaffolds and methods for their preparation
US20030229105A1 (en) 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ[2,3−d]ピリミジン−4−イルおよびプリン−6−イル尿素化合物
US20050124637A1 (en) 2003-08-15 2005-06-09 Irm Llc Compounds and compositions as inhibitors of receptor tyrosine kinase activity
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
GB0407723D0 (en) 2004-04-05 2004-05-12 Novartis Ag Organic compounds
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
NZ556248A (en) 2005-03-14 2010-06-25 Neurosearch As Pyrazolyl-quinazoline potassium channel modulating agents and their medical use
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
JP2008540685A (ja) 2005-05-19 2008-11-20 シーブイ・セラピューティクス・インコーポレイテッド A1アデノシンレセプターアゴニスト
ATE414703T1 (de) 2005-09-19 2008-12-15 Hoffmann La Roche Isoxazolderivate als inverse gaba a alpha5 agonisten
AU2006301376A1 (en) 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
CN101304994B (zh) 2005-11-09 2011-06-29 弗·哈夫曼-拉罗切有限公司 3-芳基-异噁唑-4-羰基-苯并呋喃衍生物
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
AU2006328602B2 (en) 2005-12-23 2012-05-31 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
PT1968973E (pt) 2005-12-27 2011-12-09 Hoffmann La Roche Derivados de aril-isoxazol-4-il-imidazol
JP4864982B2 (ja) 2005-12-27 2012-02-01 エフ.ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾール−4−イル−イミダゾ[1,5−a]ピリジン誘導体
ATE460403T1 (de) * 2006-05-24 2010-03-15 Lilly Co Eli Verbindungen und verfahren zur modulierung von fx-rezeptoren
WO2007137954A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
JP2010502674A (ja) 2006-09-07 2010-01-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤として有用なピリジニル−ピリミジン誘導体
CA2665398A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
WO2008094737A2 (en) 2007-01-26 2008-08-07 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2008092942A2 (en) 2007-02-02 2008-08-07 Neurosearch A/S Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
US20100152210A1 (en) 2007-03-28 2010-06-17 Neuro Search A/S/ Purinyl derivatives and their use as potassium channel modulators
JP2010522719A (ja) 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
MX2009014001A (es) 2007-06-22 2010-01-28 Hoffmann La Roche Derivados de isoxazol-imidazol.
CN101827847A (zh) 2007-10-17 2010-09-08 诺瓦提斯公司 用作腺苷a1受体配体的嘌呤衍生物
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
EP2229383B1 (en) 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazine derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
JP4800445B2 (ja) * 2008-06-19 2011-10-26 武田薬品工業株式会社 複素環化合物およびその用途
WO2010034706A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
SG175333A1 (en) 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyrazole derivatives
JP5466292B2 (ja) 2009-05-05 2014-04-09 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール−ピリジン誘導体
EP2427459B1 (en) 2009-05-05 2016-09-28 F. Hoffmann-La Roche AG Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
KR101701533B1 (ko) * 2009-05-05 2017-02-13 에프. 호프만-라 로슈 아게 아이속사졸-피리다진 유도체
CA2757412C (en) 2009-05-07 2016-04-05 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives as gaba modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
ES2536667T3 (es) * 2010-11-09 2015-05-27 F. Hoffmann-La Roche Ag Derivados de triazol como ligandos de receptores Gaba
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds

Also Published As

Publication number Publication date
US20170114045A1 (en) 2017-04-27
AU2013283488A1 (en) 2015-01-15
EP2885290B1 (en) 2017-10-18
CN104411703A (zh) 2015-03-11
KR20150033679A (ko) 2015-04-01
RU2014149123A (ru) 2016-08-20
MX2014014872A (es) 2015-08-06
EP2885290A1 (en) 2015-06-24
IN2014DN11027A (enExample) 2015-09-25
US20160115155A1 (en) 2016-04-28
CA2876780A1 (en) 2014-01-03
WO2014001282A1 (en) 2014-01-03
JP2015521643A (ja) 2015-07-30
IL235991A0 (en) 2015-02-01
JP6223443B2 (ja) 2017-11-01
US9884848B2 (en) 2018-02-06
BR112014032501A2 (pt) 2017-06-27
US9475797B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
GB201304182D0 (en) No details
GB201403961D0 (en) No details
EP2717649A4 (en) HEATING ELEMENT
IL236041A0 (en) A consequence of phenyltriazole and its use to modulate the gabaa receptor complex
GB201209880D0 (en) Applicators
EP2853105A4 (en) CONTROLLED SEARCH
GB201411220D0 (en) No details
IL235991A (en) Phenyl triazole sequestration and its use in modulating the gabaa receptor complex
EP2626648B8 (en) Space heater
PL2631584T3 (pl) Grzejnik
GB2518990B (en) Controls
GB201313844D0 (en) No details
GB201403415D0 (en) No details
GB201220529D0 (en) No details available
GB201221454D0 (en) The scunthorpe urine flowstix holster
AU5123P (en) Sprilecstar Cordyline banksii
GB201211308D0 (en) Compounds for use
AU344966S (en) Sideboard
GB201206013D0 (en) The easy fix hinge
GB201322955D0 (en) No details
GB201400108D0 (en) No details
GB201206393D0 (en) Use
GB201302155D0 (en) No details
GB201300109D0 (en) No details
GB201310646D0 (en) No details

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees